Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NervGen Pharma Corp NGENF


Primary Symbol: V.NGEN

Healthcare
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a... see more

Recent & Breaking News (TSXV:NGEN)

NervGen Pharma and Massachusetts General Hospital Collaborate on Preclinical Studies in Alzheimer's Disease

Newsfile August 9, 2021

NervGen Pharma (TSXV:NGEN) closes private placement

Trevor Abes  August 5, 2021

NervGen Pharma Corp. Closes Non-Brokered Private Placement

Newsfile August 5, 2021

NervGen Pharma Grants Stock Options

Newsfile July 16, 2021

NervGen Pharma Establishes Multiple Sclerosis Clinical Advisory Board

Newsfile July 15, 2021

NervGen Pharma (TSXV:NGEN) expands Alzheimer’s disease scientific advisory board

Julia Kennedy  July 12, 2021

NervGen Pharma Expands Alzheimer's Disease Scientific Advisory Board

Newsfile July 12, 2021

NervGen Engages Vorticom Inc. to Provide Media Relations Services

Newsfile June 25, 2021

NervGen Pharma (TSXV:NGEN) partners with Sylics to study treatment for Alzheimer’s disease

Julia Kennedy  June 10, 2021

NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer's Disease Models

Newsfile June 10, 2021

NervGen Pharma Reports First Quarter 2021 Results

Newsfile May 20, 2021

NervGen Pharma (TSXV:NGEN) closes overnight marketed equity offering

John Ballem  May 12, 2021

NervGen Pharma Announces Closing of Overnight Marketed Equity Offering

Newsfile May 12, 2021

NervGen Pharma Grants Stock Options

Newsfile May 7, 2021

NervGen Pharma (TSXV:NGEN) reports first subject dosed in phase 1 clinical trial of NVG-291

Brieanna McCutcheon  May 6, 2021

NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291

Newsfile May 6, 2021

NervGen Pharma (TSXV:NGEN) announces pricing of overnight marketed equity offering

John Ballem  May 5, 2021

IIROC Trading Resumption - NGEN

Canada NewsWire May 5, 2021

NervGen Pharma Announces Pricing of Overnight Marketed Equity Offering

Newsfile May 5, 2021

IIROC Trading Halt - NGEN

Canada NewsWire May 5, 2021